1491P - Primary cardiac Sarcoma: A retrospective study in two Korean tertiary centers.

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Soft Tissue Sarcomas
Presenter Heekyung Ahn
Citation Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387
Authors H. Ahn1, H.K. Kim2, K.H. Yoo1, Y.S. Kim1, S.J. Lee2
  • 1Hematology And Oncology, Gachon University Gil Hospital, 405-760 - Incheon/KR
  • 2Division Of Hematology-oncology, Departments Of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 06351 - Seoul/KR



Primary cardiac sarcoma(PCP) is a rare diasease with dismal prognosis. Optimal treatment strategy for PCP is not clear.


We retrospectively reviewed patients diagnosed with PCS in two institutions in Korea, between 1996 and 2013. A total of 41 patients were identified. Clinical characteristics and treatment outcomes were investigated. Survival was estimated and compared by Kaplan-Meier method and Log-rank test.


Median age was 44 years. Eighteen patients (43.9%) were male. The most common type was angiosarcoma (N = 20, 48.7%), followed by poorly-differentiated sarcoma (N = 7, 17.1%). Most tumors were located in atriums (N = 27, 65.9%). At diagnosis, 31 patients (75.6%) had localized disease. Surgical resection of primary cardiac tumor was performed in 28 cases (68.3%) and microscopic complete resection were achieved in 12 localized cases. Median overall survial was 13.2 months for entire patients, 17.0 months after complete resection, 17.9 months after incomplete resection and 5.7 months in non-resected cases. Patients who received adjuvant chemotherapy and/or radiotherapy after surgery had significantly better median OS of 21.6 months than 11.0 months of those received surgical resection alone without adjuvant treatment (p = 0.007).


Surgical resection and multidisciplinary treatment were associated with better survival in patients with primary cardiac sarcomas. Aggressive multidisciplinary approaches may have a role in subset of patients with primary cardiac sarcomas.

Clinical trial identification

Legal entity responsible for the study

Hee Kyung Ahn




All authors have declared no conflicts of interest.